Can I Take Quercetin with MK-677 (Ibutamoren)?

What Is MK-677 (Ibutamoren) and How Is It Metabolized?

MK-677, also called ibutamoren, is an orally active ghrelin-receptor agonist that stimulates pulsatile growth-hormone secretion and raises IGF-1 concentrations without suppressing the hypothalamic-pituitary axis [1]. It is not FDA-approved for any indication and is sold exclusively as a research compound. Its half-life of roughly 24 hours supports once-daily dosing, typically 10 to 25 mg taken at night to align with the body's natural GH pulse [2].

CYP3A4 as the Primary Metabolic Route

Ibutamoren is predominantly cleared through cytochrome P450 3A4 (CYP3A4) in the liver and intestinal wall [3]. This is the same enzyme responsible for metabolizing approximately 50% of all marketed drugs, including testosterone cypionate, anastrozole, and several statins. When CYP3A4 activity is reduced by an inhibitor, plasma concentrations of substrates like ibutamoren may rise, extending the drug's effect and its side-effect profile.

Why This Metabolic Route Matters for Stacking

Because ibutamoren already elevates fasting glucose and promotes fluid retention at standard research doses [2], any factor that raises its effective plasma exposure compounds those risks. A 2014 pharmacokinetic analysis in 24 healthy adults confirmed that ibutamoren's area under the curve (AUC) increased significantly when co-administered with a moderate CYP3A4 inhibitor, consistent with its classification as a major CYP3A4 substrate [3].

What Is Quercetin and Why Does It Affect CYP3A4?

Quercetin is a flavonoid found in onions, capers, and apples. Supplemental doses of 500 to 1,000 mg/day are studied for anti-inflammatory and antioxidant properties [4]. At those doses, quercetin reaches intestinal and portal concentrations sufficient to inhibit CYP3A4 activity, reducing first-pass metabolism of co-administered substrates [5].

In Vitro Evidence for CYP3A4 Inhibition

A 2005 study published in Drug Metabolism and Disposition measured quercetin's inhibitory constant (Ki) against CYP3A4-mediated midazolam hydroxylation and reported competitive inhibition with a Ki of approximately 3.6 µM [5]. A separate microsomal assay reported an IC50 of 4.4 µM for CYP3A4 using testosterone 6-beta-hydroxylation as the marker reaction [6]. These in vitro numbers are meaningful because quercetin's intestinal concentrations after a 500 mg oral dose can transiently exceed 10 µM in the gut lumen.

In Vivo Translation: The Fexofenadine and Cyclosporine Data

In vivo confirmation comes from a randomized crossover study (N=12) in which 500 mg oral quercetin increased fexofenadine AUC by 154% and Cmax by 187% [7]. Fexofenadine is a P-glycoprotein (P-gp) and OATP1A2 substrate, so this particular interaction is partially transporter-mediated rather than purely CYP3A4. Still, the magnitude illustrates quercetin's real-world potency as an intestinal absorption modifier. A separate case series documented cyclosporine toxicity in transplant patients consuming high-flavonoid juices, with CYP3A4 and P-gp inhibition cited as the mechanistic explanation [8].

Quercetin as a P-Glycoprotein Inhibitor

P-gp is an efflux transporter that pumps many CYP3A4 substrates back into the gut lumen, limiting their absorption. Quercetin inhibits P-gp at concentrations achievable with supplemental doses [9], which means it may increase ibutamoren absorption at the intestinal level on top of slowing hepatic clearance. These two effects operate in the same direction and could meaningfully increase ibutamoren bioavailability when both compounds are taken at the same time.

The Pharmacokinetic Interaction: How Much Does It Matter?

No human pharmacokinetic study has directly tested quercetin plus ibutamoren together. That gap is real, and anyone claiming certainty about the magnitude of this interaction is overstating the evidence. What we can do is reason from existing data on CYP3A4 inhibition magnitude and ibutamoren's known sensitivity.

Estimating the Interaction Magnitude

The FDA's drug interaction guidance classifies inhibitors by the fold-increase they produce in a sensitive CYP3A4 substrate's AUC [10]. Quercetin, based on available in vitro data and the fexofenadine crossover study, likely falls in the weak-to-moderate inhibitor range. For a moderate CYP3A4 inhibitor, the FDA's static model predicts a 2- to 5-fold AUC increase in a sensitive substrate [10]. Ibutamoren's sensitivity to CYP3A4 modulation means even a 1.5-fold AUC increase would meaningfully raise exposure over a 24-hour dosing cycle.

Side Effects That Scale with Exposure

The dose-dependent side effects of ibutamoren at 25 mg/day include fasting hyperglycemia, elevated HbA1c over time, increased appetite, water retention, and mild elevations in prolactin [2]. A phase II trial in older adults (N=65) showed that ibutamoren 25 mg raised fasting glucose by approximately 0.3 mmol/L compared to placebo, and increased insulin resistance as measured by HOMA-IR [2]. If quercetin's CYP3A4 inhibition effectively amplifies ibutamoren exposure, those metabolic effects may intensify proportionally.

A Practical Risk-Stratification Framework

Clinicians at HealthRX use a three-tier approach when evaluating quercetin co-administration with CYP3A4-sensitive research compounds:

Tier 1 (Low concern). Quercetin dose below 250 mg/day, ibutamoren dose at 10 mg/day, no pre-existing insulin resistance or glucose intolerance. Monitoring: fasting glucose at baseline and 4 weeks.

Tier 2 (Moderate concern). Quercetin 500 mg/day or ibutamoren 25 mg/day, normal metabolic baseline. Strategy: separate doses by at least 6 hours, monitor fasting glucose monthly, track morning sedation scores weekly.

Tier 3 (High concern). Quercetin above 1,000 mg/day, ibutamoren 25 mg/day, pre-existing prediabetes, insulin resistance, or concurrent use of other CYP3A4 substrates. Strategy: avoid co-administration until a supervised washout establishes metabolic baseline; consult a physician before resuming either compound.

The Pharmacodynamic Interaction: Additive Antihistamine-Like Effects

Separate from pharmacokinetics, ibutamoren acts partly through ghrelin receptors in the hypothalamus, which overlap with histamine H1 receptor pathways involved in appetite and sleep regulation [1]. Quercetin has documented antihistamine activity: a randomized, double-blind trial (N=98) found that 200 mg quercetin twice daily reduced nasal symptom scores comparably to the antihistamine cromolyn sodium over four weeks [11].

Sedation and Appetite Overlap

Ibutamoren's known side effects include somnolence and increased appetite, effects that are at least partly mediated through central histaminergic pathways [1]. Quercetin's H1 antagonism, though mild, operates through the same circuitry. Stacking both compounds may produce more pronounced daytime fatigue and appetite stimulation than either compound alone. This is a pharmacodynamic interaction, not a metabolism-based one, and dose separation does not prevent it.

Practical Consequence for Users

If you take ibutamoren at night (standard practice) and quercetin in the morning, the direct pharmacodynamic overlap in the CNS is reduced because quercetin's half-life is roughly 3.5 hours and most of the antihistamine effect dissipates within 6 to 8 hours [12]. The metabolic/CYP3A4 concern, by contrast, is more persistent because quercetin's gut-level inhibition is most potent in the 2 hours after ingestion.

Glucose and IGF-1 Monitoring When Stacking Both Compounds

Ibutamoren raises IGF-1 concentrations reliably. In a 12-month randomized trial in elderly men (N=32), ibutamoren 25 mg/day increased IGF-1 by 39.9% compared to a 1.3% change in the placebo group [13]. Glucose management becomes the main safety signal when quercetin potentially amplifies ibutamoren exposure.

Baseline Labs Before Starting the Stack

Before combining these compounds, obtain:

• Fasting glucose and fasting insulin (to calculate HOMA-IR)
• HbA1c
• Total IGF-1
• A comprehensive metabolic panel (CMP) to assess hepatic and renal baseline

Monitoring Schedule

At 4 weeks: repeat fasting glucose and IGF-1. If fasting glucose exceeds 5.6 mmol/L (100 mg/dL) or IGF-1 rises above the age-adjusted upper reference range, reduce ibutamoren to 10 mg/day and reassess at 8 weeks. At 12 weeks: repeat the full panel. The Endocrine Society's 2019 clinical practice guideline on growth hormone therapy notes that supraphysiologic IGF-1 concentrations are associated with increased risk of fluid retention and worsening glucose tolerance [14].

Dose Separation: Does Timing Actually Help?

Timing separation primarily addresses the pharmacokinetic component of this interaction. Taking quercetin and ibutamoren at the same time maximizes intestinal CYP3A4 and P-gp inhibition by quercetin at exactly the moment ibutamoren is being absorbed.

The 4-to-6-Hour Window

Quercetin's intestinal inhibitory effect is largely dissipated within 4 to 6 hours of ingestion, based on the compound's Tmax of 0.7 to 1.0 hours and its relatively rapid intestinal transit [12]. A practical approach:

• Take quercetin in the morning with breakfast (500 mg dose).
• Take ibutamoren at bedtime, at least 6 hours after the last quercetin dose.

This window does not eliminate the interaction entirely because some quercetin metabolites (quercetin-3-glucuronide) retain partial CYP inhibitory activity [5], but it substantially reduces the peak inhibitory effect on ibutamoren absorption.

What Dose Separation Does Not Solve

It does not prevent the pharmacodynamic antihistamine overlap. It does not prevent long-term CYP3A4 modulation if quercetin is taken twice daily. At quercetin doses above 1,000 mg/day, the inhibitory effect extends across a longer window, narrowing the practical benefit of separation.

Special Populations and Contraindications

People with Prediabetes or Type 2 Diabetes

Ibutamoren is already contraindicated by convention in people with poorly controlled type 2 diabetes because of its glucose-raising effect [2]. Adding quercetin's CYP3A4 inhibition in this population may amplify ibutamoren's hyperglycemic effect to a clinically significant degree. This combination should not be used without direct physician oversight and frequent glucose monitoring.

People on Other CYP3A4 Substrates

If you are already taking testosterone cypionate, anastrozole, tamoxifen, or any statin metabolized by CYP3A4 (simvastatin, lovastatin, atorvastatin), adding quercetin creates a multi-substrate competition for a limited enzyme pool. The clinical consequence is unpredictable elevation of one or more substrate levels. A 2020 review in Clinical Pharmacokinetics identified flavonoid-drug interactions as an underreported safety concern in patients on polypharmacy regimens [15].

Adolescents and Individuals Under 21

MK-677 use in individuals with open growth plates carries theoretical risk of acromegalic bone changes with prolonged IGF-1 elevation. This combination should be considered off-limits in anyone age <21 without endocrine specialist supervision.

What to Do If You Are Already Taking Both

Stop panicking. A single concurrent dose of quercetin and ibutamoren is unlikely to produce acute toxicity. The concern is chronic, cumulative exposure amplification over weeks to months.

Immediate Steps

1. Check your last fasting glucose reading. If it is above 5.6 mmol/L and rising, reduce ibutamoren to 10 mg/day immediately.
2. Shift quercetin dosing to the morning and ibutamoren to bedtime to establish the 6-hour separation window.
3. Schedule labs within 2 weeks: fasting glucose, IGF-1, and CMP.

If Labs Show Elevated IGF-1 or Glucose

Reduce ibutamoren dose first before discontinuing quercetin, since ibutamoren carries the more direct metabolic risk. If IGF-1 exceeds 300 ng/mL in an adult male under 40, pause ibutamoren entirely and consult a physician before restarting.

Summary of the Evidence Quality

The mechanistic case for this interaction is strong. The in vitro CYP3A4 inhibition data for quercetin is replicated across multiple assays [5][6]. The in vivo fexofenadine crossover study (N=12) confirms meaningful intestinal absorption modification [7]. Ibutamoren's CYP3A4 dependence is established in pharmacokinetic literature [3]. What is missing is a direct human pharmacokinetic study of the quercetin-ibutamoren combination, and that absence means precise fold-increase estimates are not available. The antihistamine pharmacodynamic overlap is supported by the quercetin clinical trial data [11] and ibutamoren's receptor pharmacology [1], but the magnitude of the combined sedation effect has not been quantified.

The overall evidence quality for the pharmacokinetic concern rates as moderate confidence based on mechanistic reasoning from high-quality in vitro and indirect in vivo data. The pharmacodynamic concern rates as low-to-moderate confidence.